N 556

structure given in first source; prodrug for disodium cromoglycate

Also Known As:

1,3-bis-(2-ethoxycarbonylchromon-5-yloxy)-2-(lysyloxy)propane; KY 556; KY-556; N-556; L-Lysine, 2-((2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl)oxy)-1-(((2-(ethoxycarbonyl)-4-oxo-4H-1-benzopyran-5-yl)oxy)methyl)ethyl ester, dihydrochloride

Networked: 53 relevant articles (1 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromones: 159
        N 556: 53
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromones: 159
        N 556: 53

Experts

1.	Carter, Kim W: 2 articles (01/2021 - 10/2008)
2.	Antunez Flores, Oscar: 1 article (01/2022)
3.	As-Sanie, Sawsan: 1 article (01/2022)
4.	Chan, Noel Y: 1 article (01/2022)
5.	Chiuve, Stephanie: 1 article (01/2022)
6.	Cross, Sarah: 1 article (01/2022)
7.	Dillon, Simon T: 1 article (01/2022)
8.	Eichner, Samantha: 1 article (01/2022)
9.	Elias, Jack A: 1 article (01/2022)
10.	Fong, Tamara G: 1 article (01/2022)

Related Diseases

1.	Aneurysm (Aneurysms) 08/01/2013 - "Between 2001 and 2005, a total of 10,557 patients were identified who underwent elective open thoracic aneurysm repair, with a significantly greater proportion of white patients (n = 8524) compared with black patients (n = 819), Hispanic patients (n = 556), and patients categorized as other (n = 658). " 01/01/2009 - "Hemorrhage rates were 4.61% per year for the entire cohort (n=678), 7.48% per year for bAVMs with initial hemorrhagic presentation (n=258), 4.16% per year for initial seizure presentation (n=260), 3.99% per year for patients not harboring aneurysms (n=556), 6.93% per year for patients with associated aneurysms (n=122), and 5.42% per year for bAVMs with deep venous drainage (n=365). "
2.	Systolic Heart Failure 01/01/2022 - "In the DANISH trial, 1116 patients with nonischemic systolic heart failure were randomized to receive an ICD (N=556) or usual clinical care (N=550). "
3.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2011 - "Data were pooled from clinical studies of 3-12 months' duration in patients with moderate-to-severe COPD receiving double-blind indacaterol 75 μg (n = 449), 150 μg (n = 2611), 300 μg (n = 1157), or 600 μg once daily (n = 547); formoterol 12 μg twice daily (n = 556); salmeterol 50 μg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 μg once daily, given open label or blinded (n = 1214). "
4.	Panic Disorder (Panic Attack) 04/23/2013 - "For this purpose, persons (18-65 years) with a current (N=1273) or remitted (N=459) anxiety disorder (generalized anxiety disorder, social phobia, panic disorder, agoraphobia) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and healthy controls (N=556) were selected from the Netherlands Study of Depression and Anxiety. "
5.	Vision Disorders (Hemeralopia) 12/01/2004 - "All visually impaired individuals from 0 to 17 years of age who were born at full term from 1972 through 1989 in Finland and recorded in the Finnish Register of Visual Impairment (n = 556) were eligible for this study. "

Related Drugs and Biologics

1.	Enoxaparin (Lovenox)
2.	Proteins (Proteins, Gene)
3.	Creatinine
4.	Blood Proteins (Serum Proteins)
5.	Antithrombins
6.	Tenecteplase
7.	Eptifibatide (Integrilin)
8.	Tirofiban (Aggrastat)
9.	Interferon alpha-2 (Roferon-A)
10.	Tiotropium Bromide (Spiriva)

Related Therapies and Procedures

1.	Therapeutics
2.	Percutaneous Coronary Intervention
3.	Thrombolytic Therapy
4.	Plasma Exchange
5.	Length of Stay